Xenon Pharmaceuticals Inc (id:6426 XENE)
41.15 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 12:23:56 PM)
Exchange closed, opens in 1 day 21 hours
About Xenon Pharmaceuticals Inc
Market Capitalization 3.04B
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
| Headquarters (address) |
3650 Gilmore Way Burnaby V5G 4W8 BC Canada |
| Phone | 604 484 3300 |
| Website | https://www.xenon-pharma.com |
| Employees | 251 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | XENE |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 28.20 - 50.99 |
| Market Capitalization | 3.04B |
| P/E trailing | -15.07 |
| P/E forward | -11.19 |
| Price/Book | 3.24 |
| Beta | 1.25 |
| EPS | -2.81 |
| EPS Canada (ID:82, base:722) | 1.84 |